Fortune Business Insights has predicted that the HIV/AIDS Drugs Market will reach US$ 40.6 Bn by 2026, thereby exhibiting a CAGR of 6.1% in the forecast period.
The global HIV/AIDS drugs market is likely to derive growth form the increasing prevalence of the disease across the world. According to a report published by Fortune Business Insights, titled “HIV/AIDS Drugs Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 25,314.0 Mn in 2018.
Some of the major companies that are present in the HIV/AIDS Drugs Market
- ViiV Healthcare
- Gilead Sciences
- Merck Sharp & Dohme
- Bristol-Myers Squibb Company
- Janssen Pharmaceuticals
- Mylan Pharmaceuticals
Browse Complete Report:
The increasing awareness regarding the severity of HIV AIDS as created a huge emphasis on several drugs, related to the treatment of this disease. The side effects of HIV/AIDS have led to several drug innovations, particularly aimed at efficient treatment of patients with advanced stages of the disease. The report encompasses several factors that have contributed to the growth of the global market in recent years. Besides growth stimulators, the report highlights a few of the factors that have restrained market growth in recent years.
“Increasing Drug Approvals Will Enable Market Growth”
The increasing emphasis on the research and development of HIV/AIDS drugs has led to several drug innovations in recent years. The increasing demand for therapeutic procedures and treatment methods has created a subsequent emphasis on the development of related drugs. Fortune Business Insights has predicted that the increasing emphasis on HIV/AIDS treatment will encourage regulatory authorities to approve the usage of proposed drugs. Fortune Business Insights has identified growing regulatory approvals as one of the primary growth stimulators that have constituted a substantial amount of global HIV/AIDS drugs market value in recent years.
In April 2019, the Food and Drug Administration (FDA) passed an approval for the Dovato, a drug aimed at treatment of treatment of HIV-1 in patients with no antiretroviral (ARV) treatment history. In June 2018, the Food and Drug Administration passed an approval for Merck’s Delstrigo for the treatment of HIV-1. Fortune Business Insights has predicted that major drug approvals will have a direct impact on the global HIV/AIDS drugs market in the forthcoming years. The report encompasses several drug approvals of recent years.
Get Sample PDF Brochure:
Major Segmentation for Global HIV/AIDS Drugs Market are;
By Drug Class
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Integrase Inhibitors
- Combination HIV Medicines
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America (the USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Rest of the World
“Increasing Prevalence of HIV/AIDS will Create Growth Opportunities”
The rising prevalence of HIV/AIDS has resulted in increasing emphasis on the development of treatment methods and drugs associated with the treatment of this disease. According to data published by the Joint United Nations Program in 2018, around 37.9 million people in the world are diagnosed with HIV/AIDS. Among the 37.9 million people, around 23.3 million people were undergoing antiretroviral therapy.
Due to the increasing incidence of HIV/AIDS across the world, the HIV/AIDS drugs companies have witnessed massive growth opportunities in recent years. The large patient pool will offer a huge potential for growth of several companies in the market, which in turn, will have a direct impact on the global HIV/AIDS drugs market in the forthcoming years. The report includes several factors that constituted an increase in the global HIV/AIDS market value in recent years.
Fortune Business Insights has profiled a few of the prominent companies that have contributed to the growth of the global HIV/AIDS drugs market in recent years. Besides, Fortune Business Insights identifies some of the key strategies adopted by a few of these companies.
More Trending Topics from Fortune Business Insights:
Contraceptives Market Size, Share and Global Trend By Product Type (Contraceptive Drugs & Contraceptive Devices), By Gender (Male & Female), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGO & Others), and Geography Forecast till 2025
Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, others), and Geography Forecast till 2025
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245